Dec 06, 2018 8:30am EST Veru to Report Fiscal Year 2018 Financial Results, Host Conference Call on December 13th
Dec 03, 2018 8:30am EST Veru Announces First Patient Dosed in Bioequivalence Clinical Trial for Combination Tadalafil – Finasteride Tablet for Benign Prostatic Hyperplasia
Nov 13, 2018 8:30am EST Veru Advances Novel, First-in-Class Oral Tubulin Inhibitor for Refractory Metastatic Prostate Cancer
Oct 01, 2018 7:30am EDT First Patient Enrolled in Phase 2 Study of Zuclomiphene Citrate for Treatment of Hot Flashes Caused by Androgen Deprivation Therapy
Sep 12, 2018 8:00am EDT Veru has Successful Pre-IND Meeting with FDA for VERU-111 Next Generation Novel Oral Anti-Tubulin Therapy for Metastatic Prostate Cancer
Aug 30, 2018 8:00am EDT Veru to Ring NASDAQ Closing Bell on August 31 to Kick Off National Prostate Cancer Awareness Month
Aug 29, 2018 8:00am EDT Veru Announces Additional Information Regarding its South Africa Female Condom Tender Award
